Geron Past Earnings Performance
Past criteria checks 0/6
Geron's earnings have been declining at an average annual rate of -25.3%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 76.4% per year.
Key information
-25.3%
Earnings growth rate
-1.4%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 76.4% |
| Return on equity | -68.8% |
| Net Margin | -682.5% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Geron makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 29 | -201 | 125 | 0 |
| 30 Jun 24 | 1 | -220 | 108 | 0 |
| 31 Mar 24 | 1 | -201 | 85 | 0 |
| 31 Dec 23 | 0 | -184 | 70 | 0 |
| 30 Sep 23 | 0 | -175 | 70 | 0 |
| 30 Jun 23 | 0 | -171 | 60 | 0 |
| 31 Mar 23 | 0 | -150 | 51 | 0 |
| 31 Dec 22 | 1 | -142 | 45 | 0 |
| 30 Sep 22 | 2 | -131 | 32 | 0 |
| 30 Jun 22 | 1 | -117 | 30 | 0 |
| 31 Mar 22 | 1 | -118 | 30 | 0 |
| 31 Dec 21 | 1 | -116 | 31 | 0 |
| 30 Sep 21 | 0 | -108 | 30 | 0 |
| 30 Jun 21 | 0 | -101 | 30 | 0 |
| 31 Mar 21 | 0 | -87 | 28 | -4 |
| 31 Dec 20 | 0 | -76 | 27 | 0 |
| 30 Sep 20 | 0 | -81 | 25 | 0 |
| 30 Jun 20 | 0 | -76 | 23 | 0 |
| 31 Mar 20 | 0 | -75 | 22 | 2 |
| 31 Dec 19 | 0 | -69 | 22 | 0 |
| 30 Sep 19 | 1 | -47 | 21 | 1 |
| 30 Jun 19 | 1 | -37 | 20 | 2 |
| 31 Mar 19 | 1 | -30 | 19 | 5 |
| 31 Dec 18 | 1 | -27 | 19 | 0 |
| 30 Sep 18 | 1 | -27 | 19 | 3 |
| 30 Jun 18 | 1 | -28 | 20 | 2 |
| 31 Mar 18 | 1 | -28 | 20 | 2 |
| 31 Dec 17 | 1 | -28 | 19 | 3 |
| 30 Sep 17 | 1 | -29 | 19 | 3 |
| 30 Jun 17 | 6 | -26 | 18 | 3 |
| 31 Mar 17 | 6 | -28 | 19 | 3 |
| 31 Dec 16 | 6 | -30 | 19 | 3 |
| 30 Sep 16 | 6 | -30 | 19 | 4 |
| 30 Jun 16 | 37 | 1 | 19 | 5 |
| 31 Mar 16 | 37 | 1 | 18 | 6 |
| 31 Dec 15 | 36 | 0 | 18 | 8 |
| 30 Sep 15 | 36 | 0 | 18 | 10 |
| 30 Jun 15 | 1 | -37 | 17 | 11 |
| 31 Mar 15 | 1 | -37 | 17 | 12 |
| 31 Dec 14 | 1 | -36 | 17 | 12 |
| 30 Sep 14 | 1 | -36 | 16 | 12 |
| 30 Jun 14 | 1 | -35 | 15 | 12 |
| 31 Mar 14 | 1 | -35 | 15 | 12 |
| 31 Dec 13 | 1 | -38 | 16 | 14 |
Quality Earnings: GON is currently unprofitable.
Growing Profit Margin: GON is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: GON is unprofitable, and losses have increased over the past 5 years at a rate of 25.3% per year.
Accelerating Growth: Unable to compare GON's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GON is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: GON has a negative Return on Equity (-68.83%), as it is currently unprofitable.